Newswise — Cancer arises when cells lose control. Deciphering the “blueprint” of cancer cells – outlining how cancer cells hijack specific pathways for uncontrolled proliferation – will lead to more efficient ways to fight it. Now, in a joint effort, scientists from the Weizmann Institute of Science and clinicians from major hemato-oncology departments in Israel have successfully created detailed profiles of myeloma cancer in both pre-cancer stages, in newly diagnosed multiple myeloma patients, as well as post-treatment and relapse. These detailed blueprints will help in future precision diagnosis and treatment of this disease.
Multiple myeloma is the second-most-common type of blood cancer. Multiple myeloma occurs when plasma cells in the bone marrow – the cells that produce antibodies – proliferate out of control and lead to various types of organ failure and death. Despite many years of research and, thanks to new immunotherapy modalities, significant recent improvement in the survival of myeloma patients, many succumb to limited response – and all relapse. A major stumbling block in diagnosing myeloma is the fact that each patient is unique, and current blood tests are incapable of identifying early disease onset and classifying which patient should receive which treatment. For example, patients whose routine blood tests reveal some hallmarks of the disease in an early and precancerous stage are not treated, but are followed closely with a “watch and wait” strategy – however, 1% of such patients will lose this “Russian roulette” every year and develop the full-blown myeloma disease. Until recently, there had been no way to discriminate between those that will transform and those that will not.
At the Weizmann Institute of Science, Dr. Guy Ledergor, an MD/PhD, and Dr. Assaf Weiner – both in the lab of Prof. Ido Amit in the Department of Immunology – together with Prof. Amos Tanay of the Departments of Biological Regulation and Computer Science and Applied Mathematics, thought that a highly sensitive method developed by the group, known as single-cell RNA sequencing, could provide a new approach to understanding the makeup of multiple myeloma and devise new and more effective approaches to diagnosing and treating this devastating disease. With this vision in mind, the Weizmann Institute’s Bench-to-Bedside Program, headed by Prof. Gabi Barbash, facilitated an Israel-wide effort toward recruiting all of the hemato-oncology departments in Israel.
The new method sequences the RNA in thousands of individual cells from the patient’s blood or bone marrow, allowing the researchers to capture the specific gene program that is active in each individual cell. In order to understand the myeloma cancer blueprint, the scientists first generated a high-resolution model of normal plasma cells by sequencing tens of thousands of cells from a control group (healthy individuals undergoing hip replacements).
The plasma cells of the control population were highly similar within and across individuals, basically showing a single, common blueprint of normal plasma cells. Comparing the normal blueprints to the blueprints of patients revealed that the blueprints of myeloma cancer cells are extremely heterogeneous, with every patient showing their own unique blueprint, and with some patients demonstrating several tumor clones displaying more than a single blueprint in one patient.
This joint effort by clinicians and Weizmann Institute scientists has shown that it is possible to identify even a very small number of malignant cells in the blood at a very early (pre-cancerous) stage, and allow much more precise diagnosis and informed choices about treatments for each patient based on their “personalized” disease. As a result, it will also be possible to follow and monitor these patients using blood tests, which are significantly less painful than today’s bone marrow biopsies. Eventually the method might help multiple myeloma patients receive earlier and more precise treatment, and possibly prevent the relapse that often follows chemotherapy.
This study and sensitive methodology have been used for the first time in the world; the research, published in Nature Medicine, may help advance Israel to the forefront of myeloma diagnosis and treatment.
Prof. Barbash points out that these findings are just the beginning for applying single-cell RNA sequencing technologies to clinical genomic research. “We are now developing similar collaborations between hospital-based researchers and basic research scientists to advance diagnosis and treatment for other maladies."
“Single-cell genomic analysis, until now, was confined to a small number of research labs. We are constantly pushing the boundaries of the technology in ways that will make it a major clinical discovery and diagnostics tool,” says Prof. Amit. Such tracking may be useful for diagnosing early signs of many malignancies in the precancerous stage or post-chemotherapy relapse, thus becoming part of a personalized approach. It will enable decisions to be made based on the individual profiles of each patient’s cells at every stage of disease. These profiles are already being used to create targeted therapies against the cancer cells.
The researchers used a machine-learning approach to automatically identify malignant cells out of tens of thousands of cells. “We are entering an era in which measuring ‘big data’ and using machine learning will provide clinicians new insights and understanding into devastating diseases like multiple myeloma,” says Dr. Weiner. “In the future, physicians will hopefully be able to track the disease in real time and treat each patient according to a personalized disease profile, possibly even before symptoms appear,” affirms Dr. Ledergor.
Prof. Ido Amit’s research is supported by the David and Fela Shapell Family Foundation INCPM Fund for Preclinical Studies; the Kekst Family Institute for Medical Genetics; the Thompson Family Foundation Alzheimer’s Research Fund; the Adelis Foundation; the Eden and Steven Romick Post-Doctoral Fellowship Fund; the Steven B. Rubenstein Research Fund for Leukemia and Other Blood Disorders; the Alan and Laraine Fischer Foundation; Drs. Herbert and Esther Hecht; the Rising Tide Foundation; the BLG Trust; the Anita James Rosen Foundation; the Felix and Silvia Schnur Endowment Fund in Stem Cell Research; Isa Lior; the Wolfson Family Charitable Trust; Carla Hunter and Andre M. Schub; the estate of Ruth Drobnes; the estate of Simon Saretzky; the estate of Lydia Hershkovich; the estate of Alice Schwarz-Gardos; and the European Research Council. Prof. Amit is the recipient of the Helen and Martin Kimmel Award for Innovative Investigation.
Prof. Amos Tanay’s research is supported by the Ilana and Pascal Mantoux Institute for Bioinformatics, which he heads; the Helen and Martin Kimmel Award for Innovative Investigation; the Edmond de Rothschild Foundations; Prof. Amnon Shashua; the Steven B. Rubenstein Research Fund for Leukemia and Other Blood Disorders; David and Molly Bloom; the William P. and Gertrude Schweitzer Foundation; the Ruth and Samuel Rosenwasser Charitable Fund; the Wolfson Family Charitable Trust; Barry and Janet Lang; the estate of Lydia Hershkovich; the estate of Alice Schwarz-Gardos; and the European Research Council.
The Weizmann Institute of Science in Rehovot, Israel, is one of the world’s top-ranking multidisciplinary research institutions. The Institute’s 3,800-strong scientific community engages in research addressing crucial problems in medicine and health, energy, technology, agriculture, and the environment. Outstanding young scientists from around the world pursue advanced degrees at the Weizmann Institute’s Feinberg Graduate School. The discoveries and theories of Weizmann Institute scientists have had a major impact on the wider scientific community, as well as on the quality of life of millions of people worldwide.